Compare OUT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OUT | CELC |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.1B |
| IPO Year | N/A | 2017 |
| Metric | OUT | CELC |
|---|---|---|
| Price | $23.74 | $100.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $25.20 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 1.3M | 851.1K |
| Earning Date | 02-24-2026 | 11-12-2025 |
| Dividend Yield | ★ 5.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $1,811,600,000.00 | N/A |
| Revenue This Year | $0.99 | N/A |
| Revenue Next Year | $3.95 | N/A |
| P/E Ratio | $34.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.95 | $7.58 |
| 52 Week High | $24.84 | $112.64 |
| Indicator | OUT | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 54.90 |
| Support Level | $23.96 | $98.48 |
| Resistance Level | $24.31 | $103.09 |
| Average True Range (ATR) | 0.44 | 3.83 |
| MACD | -0.16 | -1.19 |
| Stochastic Oscillator | 33.43 | 18.54 |
Outfront Media Inc is a real estate investment trust involved in the ownership of advertising space on its portfolio of billboards and transit displays. The Company generates revenue in the form of rental income by allowing other companies to advertise on its properties and structures under short-term contracts. Outfront Media segments its operations into the United States and International units. Although it also owns assets in Canada and Latin America, the company derives the vast majority of its revenue from billboard advertising agreements in the U.S. Roughly half of the U.S. division's revenue comes from its displays in the New York City and Los Angeles markets. Outfront Media's customers include entities within the retail, television, healthcare, and entertainment industries.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.